# K36 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/k36-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.k36tx.com
- Total disclosed funding: $100M
- Latest round: Series B (Jun 28, 2023)
- Investors on record: 5

## About

Based in the US, K36 Therapeutics is a biotechnology company developing targeted therapies for cancer, specifically focusing on innovative solutions for multiple myeloma patients.K36 Therapeutics specializes in targeted cancer therapies, particularly KTX-1001, which focuses on treating multiple myeloma. The company is headquartered in Cambridge, US, and has raised a total of USD 70.00 mn in its latest funding round, a Series B led by Nextech, with participation from other investors including Bristol-Myers Squibb Company. The company’s CEO is Terrence Connolly.K36 Therapeutics primarily focuses on the development of KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is known to be overexpressed in approximately 20% of multiple myeloma patients due to the t(4;14) translocation. KTX-1001 is designed to provide targeted therapy for patients suffering from this specific type of cancer, addressing the underlying biological mechanisms associated with MMSET overexpression. The product aims to serve a critical need in the oncology market by offering a therapeutic solution for individuals impacted by multiple myeloma, particularly those affected by the t(4;14) genetic aberration. While the company has not disclosed specific customer demographics, it is evident that their focus is on healthcare providers, oncologists, and clinical trial participants within the oncology sector. The company aims to penetrate markets in North America and Europe, where there is a significant population of multiple myeloma patients requiring innovative treatment options.K36 Therapeutics operates on a revenue model that includes partnerships and collaborations with healthcare institutions and pharmaceutical companies, which facilitate clinical trials and the eventual commercialization of KTX-1001. The company is positioned in a B2B environment, engaging with hospitals, research organizations, and oncologists involved in the treatment of multiple myeloma. The transaction structure may involve agreements for exclusive licensing rights or co-development deals for KTX-1001. Potential pricing plans for KTX-1001 could reflect the premium nature of innovative cancer therapies, particularly as it targets a specific genetic anomaly, thus providing significant value to healthcare providers in managing complex cancer cases. The revenue generated from these transactions correlates with the successful advancement of the drug through clinical trials and its eventual market launch.In June 2023, K36 Therapeutics raised USD 70.00 mn in Series B funding led by Nextech, with participation from Bristol-Myers Squibb Company and other returning investors. The company will use the funding to support its Phase 1 study of KTX-1001 and expand its applications into additional hematological and solid tumor indications. K36 Therapeutics aims to further develop KTX-1001 and explore new markets, particularly focusing on regions in North America and Europe by targeting additional cancer indications.

## Funding rounds

- Series B, Jun 28, 2023, $70M — Atlas Venture, Eight Roads Ventures, F-Prime Capital, Nextech, Bristol-Myers Squibb Company
- Series A, Dec 9, 2021, $30M — Atlas Venture, Eight Roads Ventures, F-Prime Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Bristol-Myers Squibb Company — Series B